22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
19:00 , Apr 17, 2017 |  BC Extra  |  Clinical News

OncoMed reeling after latest Phase II failure

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $0.83 (17%) to $4.01 on Monday after it said tarextumab (OMP-59R5) failed to significantly extend progression-free survival (PFS) in the Phase II PINNACLE trial as a first-line treatment for extensive-stage...
17:48 , Apr 10, 2017 |  BC Extra  |  Clinical News

OncoMed's demcizumab fails Phase II pancreatic cancer trial

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) sank $3.21 (37%) to $5.55 on Monday after reporting that demcizumab (OMP-21M18) missed the primary endpoint in the Phase II YOSEMITE trial to treat metastatic pancreatic cancer in the first-line setting....
19:40 , Dec 20, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer; colorectal cancer Cell culture, mouse and patient sample studies suggest anti-FZD5 mAbs could help treat pancreatic, colorectal, and other RNF43-mutant cancers. In four RNF43-mutant human pancreatic ductal adenocarcinoma (PDAC) cell lines, two anti-FZD5...
22:47 , Nov 17, 2016 |  BC Week In Review  |  Clinical News

Vantictumab: Interim Ph Ib data

Interim data from 21 evaluable patients in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab on days 1 and 15 of each 28-day cycle plus Abraxane nab-paclitaxel and gemcitabine led to...
17:40 , Nov 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Cell culture and mouse studies suggest inhibiting FZD1, FZD2 and/or FZD7 could help treat Clostridium difficile infection (CDI). In a human cell line treated with TcdB, knockout of FZD1, FZD2 or FZD7 decreased cell...
07:00 , Oct 17, 2016 |  BioCentury  |  Product Development

Yes we PanCAN

A major goal of a new multidrug platform study organized by the Pancreatic Cancer Action Network is to meet patients' needs better than traditional trials do. Among other things, that means accepting patients who have...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Clinical News

Vantictumab: Phase Ib data

Top-line data from 21 evaluable patients with locally recurrent or metastatic HER2-negative breast cancer in an open-label, dose-escalation, U.S. Phase Ib trial showed that IV vantictumab plus paclitaxel led to 7 partial responses and 6...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Ipafricept: Phase Ib ongoing

OncoMed said FDA lifted a partial hold on the company's Phase Ib trials evaluating ipafricept. The trials are evaluating the product in combination with carboplatin and paclitaxel to treat recurrent platinum-sensitive ovarian cancer; in combination...
01:54 , Sep 5, 2014 |  BC Extra  |  Clinical News

FDA lifts partial hold on OncoMed's ipafricept

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said FDA lifted a partial hold on Phase Ib trials of oncology candidate ipafricept ( Fzd8-Fc, OMP-54F28), a Wnt signaling antagonist. The agency placed the hold in June after the company...